Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

HIV-Related Lymphoma Differs in Those With Early vs Advanced HIV Infection

April 1, 2002
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 4
Volume 11
Issue 4

HOUSTON-Physicians at Ben Taub General Hospital, Houston, noticed that an unusual number of patients were presenting with lymphoma as their first AIDS-defining event. This observation prompted a retrospective study of all HIV-positive patients with non-Hodgkin’s lymphoma presenting between 1989 and 2000.

HOUSTON—Physicians at Ben Taub General Hospital, Houston, noticed that an unusual number of patients were presenting with lymphoma as their first AIDS-defining event. This observation prompted a retrospective study of all HIV-positive patients with non-Hodgkin’s lymphoma presenting between 1989 and 2000.

Indeed, the analysis showed that 33 (35%) of the 88 patients identified in the study were newly diagnosed with HIV, whereas 55 were known to be HIV positive when their lymphoma was diagnosed, Suleiman Alfred Massarweh, MD, told ONI in an interview. In other cohorts of patients with HIV-related lymphoma, he noted, only 3% to 5% typically present with lymphoma as their first AIDS-defining illness.

This discrepancy may be explained, in part, by Ben Taub’s status as a community hospital. The hospital serves as the first destination for these patients at presentation, thus eliminating potential referral bias. "Most patients in the large cohorts already have their HIV diagnosis when they go to these referral centers," Dr. Massarweh said at the 43rd Annual Meeting of the American Society of Hematology (abstract 1434). He is a clinical fellow at Baylor College of Medicine.

The substantial number of newly diagnosed HIV patients with lymphoma in the Ben Taub database gave the Houston researchers a unique opportunity to compare these patients with lymphoma patients with known HIV infection.

Of the 55 known-HIV patients presenting with lymphoma in the study, 10 had no history of an AIDS-defining illness and were being followed by primary care physicians in the HIV clinic. The rest had a previous AIDS-defining event before their lymphoma presentation.

Burkitt’s Lymhoma

Dr. Massarweh noted that the new-HIV lymphoma patients tended to be a few years older than the known-HIV patients: an average of 41 vs 38 years.

A more important finding was that the new-HIV patients were significantly more likely to have Burkitt’s or Burkitt’s-like lymphoma. Conversely, the known-HIV patients, who typically were more immunocompromised, were more likely to have diffuse large B cell immunoblastic lymphoma.

In addition, gastrointestinal involvement was rare in the new-HIV patients, but was very strongly associated with known HIV. "Out of the 33 new-HIV patients, only one had GI involvement at diagnosis. The other 14 cases of GI involvement were in the known-HIV group," Dr. Massarweh said.

He noted that in most previous studies involving large cohorts, the investigators did not distinguish among different lymphoma types when determining trends in the incidence and outcome of AIDS-related lymphoma. "They put everything together," he said. "Central nervous system lymphoma should be out of the equation; it should be looked at separately because we know it occurs in very advanced patients with very low CD4 counts."

The Ben Taub cohort, he said, suggests that not all systemic lymphomas are the same either. "There is a variety that can develop in patients who do not have advanced immunosuppression, and this category may be amenable to treatments to reconstitute the immune system," he said. "These patients may be more likely to respond to their lymphoma therapy and have a chance of long survival."

The fact that patients with early HIV infection still develop lymphoma suggests, Dr. Massarweh said, that some pathogenetic pathway other than prolonged low CD4 counts may be responsible. "It might be due to other factors such as an endogenous cytokine imbalance," he said.

Articles in this issue

Infection Rate Low With Peripheral and Nontunneled CVCs Nontunneled Catheters
Virtual Shared Specimen Resource ‘Essential’
DHA Conjugate Increases Paclitaxel Uptake by Tumor Cells
Letrozole Superior to Tamoxifen in Metastatic Breast Cancer
S-8184 Paclitaxel Emulsion Promising in Phase I Study
HIV+ Veterans Have Higher Rates of Unusual Cancers
A Clinician’s Perspective on ASCO 2001: Going After the Epidermal Growth Factor Receptor
Online Breast Cancer Support Groups Beneficial
Survival Benefit With Capecitabine/Docetaxel
FDA Approves Zometa for Cancer-Related Bone Complications
New Blood Test for Early Ovarian Cancer in Clinical Trials
Race Per Se Does Not Predict Extracapsular Prostate Cancer
HIV-Related Lymphoma Differs in Those With Early vs Advanced HIV Infection
Equal Access Erases Racial Disparity in Prostate Cancer Stage
FDA Approves Zevalin for Use With Rituxan in Refractory NHL Patients
Recent Videos
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
MATTERHORN Findings May Offer Additional Therapy Option in Gastric Cancers
Making the Most of ADCs: Balancing Benefits and Managing Concerns in Ovarian Cancer
Making the Most of ADCs: Balancing Benefits and Managing Concerns in Ovarian Cancer
Advances in ADC Therapy for Ovarian Cancer
Advances in ADC Therapy for Ovarian Cancer
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
Bexmarilimab Shows Survival Efficacy in Relapsed/Refractory MDS
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Nivolumab Exhibits Enhanced DFS Outcomes in Resected Gastric Cancers
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
No Deaths Observed Related to Nivolumab in Resected Gastric Cancers
2 experts in this video
ASCO 2025: MonumenTAL-1 Extended Follow-Up for Talquetamab in R/R MM
Looking Ahead: What’s on the Horizon in Advanced Melanoma
Looking Ahead: What’s on the Horizon in Advanced Melanoma
CEPHEUS Trial: Design/Baseline Characteristics
CEPHEUS Trial: Design/Baseline Characteristics
Introduction/Treatment Overview of Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Introduction/Treatment Overview of Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Related Content
Advertisement

Elranatamab Triplet Induces Early and Deep Responses in Newly Diagnosed MM

Elranatamab Triplet Induces Early and Deep Responses in Newly Diagnosed MM

Ariana Pelosci
June 16th 2025
Article

The MagnetisMM-6 trial showed that elranatamab plus daratumumab and lenalidomide yielded an ORR of 97.3% in transplant-ineligible multiple myeloma.


Experts from Washington University in St. Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

Adopting Best Practices for Administering TROP2-Directed ADCs in NSCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
June 16th 2025
Podcast

Experts from Washington University in St. Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.


Similar response rates and safety profiles were observed with subcutaenous and intravenous isatuximab in the phase 3 IRAKLIA study.

Subcutaneous Isatuximab Shows Noninferior Efficacy in Multiple Myeloma

Kristi Rosa
June 16th 2025
Article

Similar response rates and safety profiles were observed with subcutaenous and intravenous isatuximab in the phase 3 IRAKLIA study.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


Low rates of early relapse in both arms of the phase 3 IsKia trial support the efficacy of carfilzomib in this newly diagnosed multiple myeloma setting.

Isatuximab Combination Significantly Sustains MRD Negativity in NDMM

Russ Conroy
June 16th 2025
Article

Low rates of early relapse in both arms of the phase 3 IsKia trial support the efficacy of carfilzomib in this newly diagnosed multiple myeloma setting.


TPS 31 Real-World Sacituzumab Govitecan Treatment Patterns and Outcomes in Second-Line or Later Metastatic Triple-Negative Breast Cancer: Leveraging Electronic Health Records and Manual Curation of a US Database

TPS 31 Real-World Sacituzumab Govitecan Treatment Patterns and Outcomes in Second-Line or Later Metastatic Triple-Negative Breast Cancer: Leveraging Electronic Health Records and Manual Curation of a US Database

Vikram Gorantla
June 15th 2025
Article
Related Content
Advertisement

Elranatamab Triplet Induces Early and Deep Responses in Newly Diagnosed MM

Elranatamab Triplet Induces Early and Deep Responses in Newly Diagnosed MM

Ariana Pelosci
June 16th 2025
Article

The MagnetisMM-6 trial showed that elranatamab plus daratumumab and lenalidomide yielded an ORR of 97.3% in transplant-ineligible multiple myeloma.


Experts from Washington University in St. Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

Adopting Best Practices for Administering TROP2-Directed ADCs in NSCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
June 16th 2025
Podcast

Experts from Washington University in St. Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.


Similar response rates and safety profiles were observed with subcutaenous and intravenous isatuximab in the phase 3 IRAKLIA study.

Subcutaneous Isatuximab Shows Noninferior Efficacy in Multiple Myeloma

Kristi Rosa
June 16th 2025
Article

Similar response rates and safety profiles were observed with subcutaenous and intravenous isatuximab in the phase 3 IRAKLIA study.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


Low rates of early relapse in both arms of the phase 3 IsKia trial support the efficacy of carfilzomib in this newly diagnosed multiple myeloma setting.

Isatuximab Combination Significantly Sustains MRD Negativity in NDMM

Russ Conroy
June 16th 2025
Article

Low rates of early relapse in both arms of the phase 3 IsKia trial support the efficacy of carfilzomib in this newly diagnosed multiple myeloma setting.


TPS 31 Real-World Sacituzumab Govitecan Treatment Patterns and Outcomes in Second-Line or Later Metastatic Triple-Negative Breast Cancer: Leveraging Electronic Health Records and Manual Curation of a US Database

TPS 31 Real-World Sacituzumab Govitecan Treatment Patterns and Outcomes in Second-Line or Later Metastatic Triple-Negative Breast Cancer: Leveraging Electronic Health Records and Manual Curation of a US Database

Vikram Gorantla
June 15th 2025
Article
Advertisement
Advertisement
Advertisement
Advertisement
x
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.